The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perifused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase

Cellular Physiology and Biochemistry

Volumn 20, Issue 6, 2007, Pages 925-934

  Guigas, Bruno ^a   Naboulsi, Roula ^b   Villanueva, Gloria R ^b   Taleux, Nellie ^a,c   Lopez Novoa, José M ^b   Leverve, Xavier M ^c   El Mir, Mohamad Yehia ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c INSERM   (France)

Author keywords

Flavonoid; Gluconeogenesis; Glucose 6 phosphatase; Hepatocytes; Silibinin; Type 2 diabetes

Indexed keywords

DIHYDROXYACETONE; FLAVONOID; FRUCTOSE; GLUCAGON; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATE; GLYCEROL; LACTIC ACID; PYRUVIC ACID; SILIBININ;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME KINETICS; GLUCONEOGENESIS; GLYCOGENOLYSIS; HYDROLYSIS; LIVER CELL; LIVER MICROSOME; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERFUSION; PRIORITY JOURNAL; RAT;

RATTUS;

ANIMALS; DIHYDROXYACETONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; GLUCAGON; GLUCONEOGENESIS; GLUCOSE-6-PHOSPHATASE; GLUCOSE-6-PHOSPHATE; GLYCOLYSIS; HEPATOCYTES; HYDROLYSIS; MALE; MICROSOMES, LIVER; PERFUSION; PERMEABILITY; RATS; RATS, WISTAR; SILYMARIN;

EID: 35848964400     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110453     Document Type: Article

References (39)

1. Aherne SA, O'Brien NM: Dietary flavonols: chemistry, food content, and metabolism. Nutrition 2002;18:75-81.
2. Flora K, Hahn M, Rosen H, Benner K: Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139-143.
3. Wellington K, Jarvis B: Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001;15:465-489.
4. Saller R, Meier R, Brignoli R: The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-2063.
5. Zi X, Agarwal R: Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci U S A 1999;96:7490-7495.
6. Gallo D, Giacomelli S, Ferlini C, Raspaglio G, Apollonio P, Prislei S, Riva A, Morazzoni P, Bombardelli E, Scambia G: Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Eur J Cancer 2003;39:2403-2410.
7. Saliou C, Rihn B, Cillard J, Okamoto T, Packer L: Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett 1998;440:8-12.
8. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, Hong JS, Jeng KC: Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002;16:2103-2112.
9. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M: Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997;26:871-879.
10. Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, Crepaldi G: Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr Metab 2002;15:222-231.
11. Fallah Huseini H, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M: The efficacy of silybum marianum (L.) Gaertn. (Silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 2006;20:1036-1039.
12. Maghrani M, Zeggwagh NA, Lemhadri A, El Amraoui M, Michel JB, Eddouks M: Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes mellitus. J Ethnopharmacol 2004;91:309-316.
13. Soto CP, Perez BL, Favari LP, Reyes JL: Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;119:125-129.
14. Foster JD, Nordlie RC: The biochemistry and molecular biology of the glucose-6-phosphatase system. Exp Biol Med (Maywood) 2002;227:601-608.
15. van Schaftingen E, Gerin I: The glucose-6-phosphatase system. Biochem J 2002;362:513-532.
16. Nordlie RC, Foster JD, Lange AJ: Regulation of glucose production by the liver. Annu Rev Nutr 1999;19:379-406.
17. Desvergne B, Michalik L, Wahli W: Transcriptional regulation of metabolism. Physiol Rev 2006;86:465-514.
18. Newgard CB, Foster DW, McGarry JD: Evidence for suppression of hepatic glucose-6-phosphatase with carbohydrate feeding. Diabetes 1984;33:192-195.
19. Mithieux G: New knowledge regarding glucose-6 phosphatase gene and protein and their roles in the regulation of glucose metabolism. Eur J Endocrinol 1997;136:137-145.
20. Ichai C, Guignot L, El-Mir MY, Nogueira V, Guigas B, Chauvin C, Fontaine E, Mithieux G, Leverve XM: Glucose 6-phosphate hydrolysis is activated by glucagon in a low temperature-sensitive manner. J Biol Chem 2001;276:28126- 28133.
21. Berry MN, Friend DS: High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol 1969;43:506-520.
22. Groen AK, van Roermund CW, Vervoorn RC, Tager JM: Control of gluconeogenesis in rat liver cells. Flux control coefficients of the enzymes in the gluconeogenic pathway in the absence and presence of glucagon. Biochem J 1986;237:379-389.
23. Van Der Meer R, Tager JM: A simple method for the perfusion of isolated liver cells. FEBS Lett 1976;67:36-40.
24. Zuurendonk PF, Tischler ME, Akerboom TP, Van Der Meer R, Williamson JR, Tager JM: Rapid separation of particulate and soluble fractions from isolated cell preparations (digitonin and cell cavitation procedures). Methods Enzymol 1979;56:207-223.
25. Arion WJ, Carlson PW, Wallin BK, Lange AJ: Modifications of hydrolytic and synthetic activities of liver microsomal glucose 6-phosphatase. J Biol Chem 1972;247:2551-2557.
26. Baginski ES, Epstein E, Zak B: Review of phosphate methodologies. Ann Clin Lab Sci 1975;5:399-416.
27. Pilkis SJ, Claus TH, Riou JP, Park CR: Possible role of pyruvate kinase in the hormonal control of dihydroxyacetone gluconeogenesis in isolated heptatocytes. Metabolism 1976;25:1355-1360.
28. Veneziale CM: Gluconeogenesis from D-glyceraldehyde and dihydroxyacetone in isolated rat liver. Stimulation by glucagon. Biochemistry 1972;11:3286-3289.
29. Gonzalez-Mujica F, Motta N, Estrada O, Perdomo E, Mendez J, Hasegawa M: Inhibition of hepatic neoglucogenesis and glucose-6-phosphatase by quercetin 3-O-alpha( 2′'-galloyl)rhamnoside isolated from Bauhinia megalandra leaves. Phytother Res 2005;19:624-627.
30. Estrada O, Hasegawa M, Gonzalez-Mujica F, Motta N, Perdomo E, Solorzano A, Mendez J, Mendez B, Zea EG: Evaluation of flavonoids from Bauhinia megalandra leaves as inhibitors of glucose-6-phosphatase system. Phytother Res 2005;19:859-863.
31. Agius L, Centelles J, Cascante M: Multiple glucose 6-phosphate pools or channelling of flux in diverse pathways? Biochem Soc Trans 2002;30:38-43.
32. Ovadi J, Srere PA: Macromolecular compartmentation and channeling. Int Rev Cytol 2000;192:255-280.
33. Gomis RR, Favre C, Garcia-Rocha M, Fernandez-Novell JM, Ferrer JC, Guinovart JJ: Glucose 6-phosphate produced by gluconeogenesis and by glucokinase is equally effective in activating hepatic glycogen synthase. J Biol Chem 2003;278:9740-9746.
34. Katz J, Golden S, Wals PA: Glycogen synthesis by rat hepatocytes. Biochem J 1979;180:389-402.
35. Mithieux G, Guignot L, Bordet JC, Wiernsperger N: Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 2002;51:139-143.
36. Woerle HJ, Szoke E, Meyer C, Dostou JM, Wittlin SD, Gosmanov NR, Welle SL, Gerich JE: Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 2006;290:E67-E77.
37. Croset M, Rajas F, Zitoun C, Hurot JM, Montano S, Mithieux G: Rat small intestine is an insulin-sensitive gluconeogenic organ. Diabetes 2001;50:740-746.
38. Zhao J, Agarwal R: Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 1999;20:2101-2108.
39. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, Garcea G, Farmer PB, Steward WP, Gescher AJ: Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 2006;12:2944-2950.